PMID: 18719384Aug 23, 2008Paper

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer

Cell Cycle
Dmitri LodyginHeiko Hermeking

Abstract

Recently, we and others identified the microRNA miR-34a as a target of the tumor suppressor gene product p53. Ectopic miR-34a induces a G(1) cell cycle arrest, senescence and apoptosis. Here we report that miR-34a expression is silenced in several types of cancer due to aberrant CpG methylation of its promoter. 19 out of 24 (79.1%) primary prostate carcinomas displayed CpG methylation of the miR-34a promoter and concomitant loss of miR-34a expression. CpG methylation of the miR-34a promoter was also detected in breast (6/24; 25%), lung (7/24; 29.1%), colon (3/23; 13%), kidney (3/14; 21.4%), bladder (2/6; 33.3%) and pancreatic (3/19; 15.7%) carcinoma cell lines, as well as in melanoma cell lines (19/44; 43.2%) and primary melanoma (20/32 samples; 62.5%). Silencing of miR-34a was dominant over its transactivation by p53 after DNA damage. Re-expression of miR-34a in prostate and pancreas carcinoma cell lines induced senescence and cell cycle arrest at least in part by targeting CDK6. These results show that miR-34a represents a tumor suppressor gene which is inactivated by CpG methylation and subsequent transcriptional silencing in a broad range of tumors.

Citations

Jul 20, 2012·Archives of Toxicology·José M MatésJavier Márquez
Jan 12, 2011·World Journal of Surgery·Lidong ZhangChangyi Chen
Jan 22, 2010·Apoptosis : an International Journal on Programmed Cell Death·Sarah G BaileyPaul A Townsend
Aug 3, 2011·Apoptosis : an International Journal on Programmed Cell Death·E RudolfM Cervinka
Dec 17, 2009·Cancer Metastasis Reviews·Sylvia K Shenouda, Suresh K Alahari
Jan 26, 2010·Cancer Metastasis Reviews·Gerwin HellerSabine Zöchbauer-Müller
Mar 12, 2010·Pharmaceutical Research·Sharanjot SainiRajvir Dahiya
Oct 29, 2010·Journal of Physiology and Biochemistry·Yong HuangGuo Zheng Zhang
Jan 6, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Reo MaruyamaYasuhisa Shinomura
Dec 25, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Weiguo CaoYunlin Wu
Mar 19, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lijuan LiLinbo Gao
Mar 28, 2012·Cancer Letters·Shinichi Fukushige, Akira Horii
Dec 12, 2012·Cancer Letters·Nicholas C D'AmatoJennifer K Richer
Sep 13, 2013·Mutation Research. Genetic Toxicology and Environmental Mutagenesis·Xinrong ChenTao Chen
Mar 24, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Phong TrangFrank J Slack
Jul 10, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jane ZhaoAndreas G Bader
Mar 6, 2009·Nature Reviews. Cancer·Milena S NicolosoGeorge A Calin
Aug 18, 2012·Nature Reviews. Cancer·Heiko Hermeking
Oct 5, 2010·Nature Reviews. Drug Discovery·Ramiro GarzonCarlo M Croce
Feb 8, 2011·Oncogene·E SotilloA Thomas-Tikhonenko
Jun 30, 2010·Prostate Cancer and Prostatic Diseases·S SevliM Ozen
Oct 6, 2012·Cancer Biotherapy & Radiopharmaceuticals·Xi WangHuizhong Zhang
Dec 18, 2012·Briefings in Functional Genomics·Justin A Freeman, Joaquin M Espinosa
Dec 24, 2010·Neuro-oncology·Shyamal D WeeraratneYoon-Jae Cho
May 9, 2009·Current Opinion in Nephrology and Hypertension·Samuel Saal, Scott J Harvey
Dec 2, 2008·Pigment Cell & Melanoma Research·Hunter W Richards, Estela E Medrano
Mar 26, 2011·Pigment Cell & Melanoma Research·Glen M BoyleNicholas K Hayward
Oct 19, 2011·Pigment Cell & Melanoma Research·Rachel E Bell, Carmit Levy
Nov 3, 2011·Science Signaling·Nam Hee KimStephen J Weiss
Apr 29, 2010·American Journal of Physiology. Endocrinology and Metabolism·Ting ZhaoAlex F Chen
Sep 16, 2010·Physiological Genomics·Cameron Rink, Savita Khanna
Oct 19, 2011·Journal of Skin Cancer·Daniela Göppner, Martin Leverkus
Sep 24, 2009·Cancer Research·Yunqing LiRoger Abounader
Jun 24, 2010·Cancer Research·Jason F WigginsAndreas G Bader
Feb 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David C CorneyAlexander Yu Nikitin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis